2014
DOI: 10.1093/annonc/mdu155
|View full text |Cite
|
Sign up to set email alerts
|

Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 15 publications
0
17
0
Order By: Relevance
“…Ishikawa et al [46] compared the survival rates of patients who received RFA with or without prior HAIC (DDP-H). Cumulative survival rates at 1, 3, and 5 years were 77.4%, 69.2%, and 55.3% for RFA alone, respectively, and 97.4%, 87.0%, and 84.4% for prior HAIC + RFA, respectively.…”
Section: Neo-adjuvant Therapymentioning
confidence: 99%
“…Ishikawa et al [46] compared the survival rates of patients who received RFA with or without prior HAIC (DDP-H). Cumulative survival rates at 1, 3, and 5 years were 77.4%, 69.2%, and 55.3% for RFA alone, respectively, and 97.4%, 87.0%, and 84.4% for prior HAIC + RFA, respectively.…”
Section: Neo-adjuvant Therapymentioning
confidence: 99%
“…AST: aspartate aminotransferase; ALT: alanine aminotransferase; AFP: alpha-fetoprotein; POD: post-operative day; POM: post-operative month The regimen selected for this study was 2 weeks of low-dose FP. Ishikawa et al [29,30] first reported that HAIC with cisplatin before radical local treatment (radiofrequency ablation/percutaneous ethanol injection therapy) for early-stage HCC prevented intrahepatic metastasis and prolonged the survival time. According to some clinical studies, the efficacy of low-dose FP is better than that of cisplatin alone [28] .…”
Section: Discussionmentioning
confidence: 99%
“…When we investigated the effect of the addition of TAI with DDP-H and carboplatin as pretreatment prior to TACE/radiofrequency ablation therapy as radical local treatment for stage I/II HCC, we reported that whole-liver TAI using DDP-H significantly inhibited intrahepatic recurrence (9). In addition, in patients with JIS 0–1 stage HCC, survival was significantly prolonged in the group that received whole-liver TAI with DDP-H compared with the group that did not undergo infusion, and the results of the multivariate analyses demonstrated that performing whole-liver TAI with DDP-H was a factor contributing to improved survival (10). Kim et al conducted a retrospective study on the efficacy of arterial cisplatin infusion following TACE in advanced HCC with hepatic vein invasion, and reported that, in the group of patients who underwent arterial cisplatin infusion, survival was significantly prolonged without increased adverse events, compared with that in patients who did not undergo infusion (13).…”
Section: Discussionmentioning
confidence: 99%
“…We previously reported that whole-liver transcatheter arterial infusion (TAI) with a high concentration of a fine-powder formulation of cisplatin (DDP-H) (IA-call ® ; Nippon Kayaku Co. Ltd., Tokyo, Japan) prior to radical local treatment inhibited intrahepatic recurrence of HCC (9), and that whole-liver TAI of DDP-H administered to HCC patients with a Japan Integrated Staging (JIS) score of 0–1 improved survival (10). …”
Section: Introductionmentioning
confidence: 99%